Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Conditions
Interventions
HM15211
Placebo of HM15211
Locations
60
United States
North Alabama GI Research Center
Huntsville, Alabama, United States
Synexus US - Chandler
Chandler, Arizona, United States
Precision Research Institute, LLC. (PRI)
Chula Vista, California, United States
Fresno Clinical Research Center
Fresno, California, United States
NAFLD Research Center - Altman Clinical and Translational Research Institute
La Jolla, California, United States
UC Davis Health System - Midtown Ambulatory Care Center
Sacramento, California, United States
Start Date
July 31, 2020
Primary Completion Date
June 27, 2026
Completion Date
July 27, 2026
Last Updated
November 19, 2025
NCT03587831
NCT04697810
NCT04383951
NCT02581085
NCT03997422
NCT05499949
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions